Predictive value of KRAS mutations in chemoresistant CRC

被引：30

作者：

Lievre, Astrid ^{[2
]}

Laurent-Puig, Pierre ^{[1
]}

机构：

[1] Univ Paris 05, Sch Med, F-75006 Paris, France

[2] INSERM Lab, Paris, France

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 06期

关键词：

METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; CETUXIMAB; PANITUMUMAB;

D O I：

10.1038/nrclinonc.2009.69

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

引用

页码：306 / 307

页数：3

共 10 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[3] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[4] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[5] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[6] K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy [J].

Etienne-Grimaldi, Marie-Christine ;

Formento, Jean-Louis ;

Francoual, Mireille ;

Francois, Eric ;

Formento, Patricia ;

Renee, Nicole ;

Laurent-Puig, Pierre ;

Chazal, Maurice ;

Benchimol, Daniel ;

Delpero, Jean-Robert ;

Letoublon, Christian ;

Pezet, Denis ;

Seitz, Jean-Frangois ;

Milano, Gerard .

CLINICAL CANCER RESEARCH, 2008, 14 (15) :4830-4835

[7] Cetuximab for the treatment of colorectal cancer [J].

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Karapetis, Christos S. ;

Zalcberg, John R. ;

Tu, Dongsheng ;

Au, Heather-Jane ;

Berry, Scott R. ;

Krahn, Marianne ;

Price, Timothy ;

Simes, R. John ;

Tebbutt, Niall C. ;

van Hazel, Guy ;

Wierzbicki, Rafal ;

Langer, Christiane ;

Moore, Malcolm J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048

[8] K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J].

Karapetis, Christos S. ;

Khambata-Ford, Shirin ;

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Tu, Dongsheng ;

Tebbutt, Niall C. ;

Simes, R. John ;

Chalchal, Haji ;

Shapiro, Jeremy D. ;

Robitaille, Sonia ;

Price, Timothy J. ;

Shepherd, Lois ;

Au, Heather-Jane ;

Langer, Christiane ;

Moore, Malcolm J. ;

Zalcberg, John R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (17) :1757-1765

[9] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].

Saltz, LB ;

Meropol, NJ ;

Loehrer, PJ ;

Needle, MN ;

Kopit, J ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208

[10] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [J].

Van Cutsem, E. ;

Lang, I. ;

D'haens, G. ;

Moiseyenko, V. ;

Zaluski, J. ;

Folprecht, G. ;

Tejpar, S. ;

Kisker, O. ;

Stroh, C. ;

Rougier, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 →